Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature.

Autor: Opdam M; Department of Molecular Pathology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, Netherlands., van der Noort V; Biometrics Department, Netherlands Cancer Institute, Amsterdam, Netherlands., Kleijn M; Medical Affairs, Agendia NV, Amsterdam, Netherlands., Glas A; Medical Affairs, Agendia NV, Amsterdam, Netherlands., Mandjes I; Biometrics Department, Netherlands Cancer Institute, Amsterdam, Netherlands., Kleiterp S; Department of Molecular Pathology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, Netherlands., Hilbers FS; Department of Molecular Pathology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, Netherlands., Kruger DT; Department of Molecular Pathology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, Netherlands., Bins AD; Department of Medical Oncology, Amsterdam UMC, Amsterdam, Netherlands., de Jong PC; Department of Medical Oncology, Sint-Antonius Hospital, Nieuwegein, Netherlands., Schiphorst PPJBM; Department of Internal Medicine, Streekziekenhuis Koningin. Beatrix, Winterswijk, Netherlands., van Dalen T; Department of Surgery, Diakonessenhuis, Utrecht, Netherlands., Flameling B; Department of Medical Oncology, OLVG, Amsterdam, Netherlands., Rietbroek RC; Department of Internal Medicine, Red Cross Hospital, Beverwijk, Netherlands., Beeker A; Department of Medical Oncology, Spaarne Gasthuis, Hoofddorp, Netherlands., van den Heiligenberg SM; Department of Medical Oncology, Dijklander Ziekenhuis, Hoorn, Netherlands., Bakker SD; Department of Internal Medicine, Zaans Medisch Centrum, Zaandam, Netherlands., Wymenga ANM; Department of Medical Oncology, Medisch Spectrum Twente, Enschede, Netherlands., Oving IM; Department of Medical Oncology, Ziekenhuisgroep Twente, Almelo, the Netherlands., Bijlsma RM; Department of Medical Oncology, UMCU, Utrecht, Netherlands., van Diest PJ; Department of Pathology, UMCU, Utrecht, Netherlands., Vermorken JB; Department of Medical Oncology, University Hospital Antwerp (UZA), Edegem, Belgium.; Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium., van Tinteren H; Biometrics Department, Netherlands Cancer Institute, Amsterdam, Netherlands.; Trial and Data Center, Princess Maxima Centre for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.; Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, Netherlands., Linn SC; Department of Molecular Pathology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, Netherlands. s.linn@nki.nl.; Department of Medical Oncology, UMCU, Utrecht, Netherlands. s.linn@nki.nl.; Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, Netherlands. s.linn@nki.nl.

Publikováno v: Breast cancer research and treatment [Breast Cancer Res Treat] 2022 Jul; Vol. 194 (2), pp. 265-278. Date of Electronic Publication: 2022 May 19.

IGF-1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER-positive breast cancer.

Autor: Kruger DT; Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam/Cancer Center Amsterdam, Amsterdam, The Netherlands.; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Alexi X; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Opdam M; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Schuurman K; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Voorwerk L; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Sanders J; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., van der Noort V; Division of Biometrics, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Boven E; Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam/Cancer Center Amsterdam, Amsterdam, The Netherlands., Zwart W; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands., Linn SC; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Medical Oncology, The National Cancer Institute, Amsterdam, The Netherlands.; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.

Publikováno v: International journal of cancer [Int J Cancer] 2020 Apr 15; Vol. 146 (8), pp. 2348-2359. Date of Electronic Publication: 2019 Oct 06.

High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2- postmenopausal breast cancer patients treated with everolimus and exemestane.

Autor: Kruger DT; Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam/Cancer Center Amsterdam, The Netherlands., Jansen MPHM; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Konings IRHM; Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam/Cancer Center Amsterdam, The Netherlands., Dercksen WM; Department of Medical Oncology, Maxima Medical Centre, Eindhoven, The Netherlands., Jager A; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Oulad Hadj J; Department of Medical Oncology, Gelre Ziekenhuis, Apeldoorn, The Netherlands., Sleijfer S; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Martens JWM; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Boven E; Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam/Cancer Center Amsterdam, The Netherlands.

Publikováno v: Molecular oncology [Mol Oncol] 2020 Mar; Vol. 14 (3), pp. 490-503. Date of Electronic Publication: 2020 Feb 07.

Hierarchical clustering of activated proteins in the PI3K and MAPK pathways in ER-positive, HER2-negative breast cancer with potential therapeutic consequences.

Autor: Kruger DT; Department of Medical Oncology, VU University Medical Centre, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.; Division of Molecular Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands., Beelen KJ; Division of Molecular Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.; Department of Medical Oncology, Reinier de Graaf Groep, Reinier de Graafweg 5, 2625 AD, Delft, The Netherlands., Opdam M; Division of Molecular Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands., Sanders J; Department of Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands., van der Noort V; Division of Biometrics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands., Boven E; Department of Medical Oncology, VU University Medical Centre, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands., Linn SC; Division of Molecular Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. s.linn@nki.nl.; Department of Medical Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. s.linn@nki.nl.; Department of Pathology, University Medical Centre Utrecht, and Utrecht University, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands. s.linn@nki.nl.

Publikováno v: British journal of cancer [Br J Cancer] 2018 Oct; Vol. 119 (7), pp. 832-839. Date of Electronic Publication: 2018 Oct 05.